Cargando…

A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery

OBJECTIVE: The study was designed to construct and validate a nomogram for predicting overall survival (OS) of male breast cancer (MBC) patients with infiltrating duct carcinoma (IDC). METHODS: The cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database between Janua...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Xin, Sun, Mei-yang, Jia, Hong-yao, Wang, Min, Cao, Ling, Li, Zhi-wen, Wang, Dun-wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796958/
https://www.ncbi.nlm.nih.gov/pubmed/31632852
http://dx.doi.org/10.7717/peerj.7837
_version_ 1783459720270446592
author Chai, Xin
Sun, Mei-yang
Jia, Hong-yao
Wang, Min
Cao, Ling
Li, Zhi-wen
Wang, Dun-wei
author_facet Chai, Xin
Sun, Mei-yang
Jia, Hong-yao
Wang, Min
Cao, Ling
Li, Zhi-wen
Wang, Dun-wei
author_sort Chai, Xin
collection PubMed
description OBJECTIVE: The study was designed to construct and validate a nomogram for predicting overall survival (OS) of male breast cancer (MBC) patients with infiltrating duct carcinoma (IDC). METHODS: The cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database between January 1, 2004 and December 31, 2013. Univariate and multivariate Cox proportional hazard (PH) regression models were performed. A nomogram was developed based on the significant prognostic indicators of OS. The discriminatory and predictive capacities of nomogram were assessed by Harrell’s concordance index (C-index), calibration plots, area under the curve (AUC) and the decision curve analysis (DCA). RESULTS: The median and maximal survival time of 1862 eligible patients were 49 and 131 months, respectively. Multivariate analysis showed that age (P < 0.0001), marital status (P = 0.002), T stage (P < 0.0001), N stage (P = 0.021), M stage (P < 0.0001), progesterone receptor (PR) (P = 0.046), human epidermal growth factor receptor-2 (HER2) (P = 0.009), and chemotherapy (P = 0.003) were independent prognostic indicators of IDC of MBC. The eight variables were then combined to construct a 3-and 5-year nomogram. The C-indexes of the nomogram were0.740 (95% confidence interval [CI] [0.709–0.771]) and 0.718 (95% CI [0.672–0.764]) for the internal validation and external validation, respectively. A better discriminatory capacity was observed in the nomogram compared with the SEER summary stage (P < 0.001) and AJCC TNM staging systems (6th edition; P < 0.001) with respect to OS prediction. Good consistency was detected between the nomogram prediction and actual findings, as indicated by calibration curves. The AUC for 3-and 5-year OS was 0.739 (95% CI [0.693–0.786]) and 0.764 (95% CI [0.725–0.803]) in the training cohort and 0.737 (95% CI [0.671–0.803]) and 0.735 (95% CI [0.678–0.793]) in the validation cohort, respectively. The DCA demonstrated that the survival nomogram was clinically useful. CONCLUSIONS: The nomogram was able to more accurately predict 3-and 5-year OS of MBC patients with IDC histology than were existing models.
format Online
Article
Text
id pubmed-6796958
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-67969582019-10-18 A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery Chai, Xin Sun, Mei-yang Jia, Hong-yao Wang, Min Cao, Ling Li, Zhi-wen Wang, Dun-wei PeerJ Bioinformatics OBJECTIVE: The study was designed to construct and validate a nomogram for predicting overall survival (OS) of male breast cancer (MBC) patients with infiltrating duct carcinoma (IDC). METHODS: The cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database between January 1, 2004 and December 31, 2013. Univariate and multivariate Cox proportional hazard (PH) regression models were performed. A nomogram was developed based on the significant prognostic indicators of OS. The discriminatory and predictive capacities of nomogram were assessed by Harrell’s concordance index (C-index), calibration plots, area under the curve (AUC) and the decision curve analysis (DCA). RESULTS: The median and maximal survival time of 1862 eligible patients were 49 and 131 months, respectively. Multivariate analysis showed that age (P < 0.0001), marital status (P = 0.002), T stage (P < 0.0001), N stage (P = 0.021), M stage (P < 0.0001), progesterone receptor (PR) (P = 0.046), human epidermal growth factor receptor-2 (HER2) (P = 0.009), and chemotherapy (P = 0.003) were independent prognostic indicators of IDC of MBC. The eight variables were then combined to construct a 3-and 5-year nomogram. The C-indexes of the nomogram were0.740 (95% confidence interval [CI] [0.709–0.771]) and 0.718 (95% CI [0.672–0.764]) for the internal validation and external validation, respectively. A better discriminatory capacity was observed in the nomogram compared with the SEER summary stage (P < 0.001) and AJCC TNM staging systems (6th edition; P < 0.001) with respect to OS prediction. Good consistency was detected between the nomogram prediction and actual findings, as indicated by calibration curves. The AUC for 3-and 5-year OS was 0.739 (95% CI [0.693–0.786]) and 0.764 (95% CI [0.725–0.803]) in the training cohort and 0.737 (95% CI [0.671–0.803]) and 0.735 (95% CI [0.678–0.793]) in the validation cohort, respectively. The DCA demonstrated that the survival nomogram was clinically useful. CONCLUSIONS: The nomogram was able to more accurately predict 3-and 5-year OS of MBC patients with IDC histology than were existing models. PeerJ Inc. 2019-10-14 /pmc/articles/PMC6796958/ /pubmed/31632852 http://dx.doi.org/10.7717/peerj.7837 Text en ©2019 Chai et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Bioinformatics
Chai, Xin
Sun, Mei-yang
Jia, Hong-yao
Wang, Min
Cao, Ling
Li, Zhi-wen
Wang, Dun-wei
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title_full A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title_fullStr A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title_full_unstemmed A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title_short A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
title_sort prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery
topic Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796958/
https://www.ncbi.nlm.nih.gov/pubmed/31632852
http://dx.doi.org/10.7717/peerj.7837
work_keys_str_mv AT chaixin aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT sunmeiyang aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT jiahongyao aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT wangmin aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT caoling aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT lizhiwen aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT wangdunwei aprognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT chaixin prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT sunmeiyang prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT jiahongyao prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT wangmin prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT caoling prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT lizhiwen prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery
AT wangdunwei prognosticnomogramforoverallsurvivalinmalebreastcancerwithhistologyofinfiltratingductcarcinomaaftersurgery